心力衰竭
医学
受体
内科学
肾上腺素能受体
心脏病学
肾上腺素能的
变向性
儿茶酚胺
心绞痛
药理学
心肌梗塞
作者
Jiandong Zhang,Paul C. Simpson,Brian C. Jensen
出处
期刊:American Journal of Physiology-heart and Circulatory Physiology
[American Physiological Society]
日期:2021-02-01
卷期号:320 (2): H725-H733
被引量:23
标识
DOI:10.1152/ajpheart.00621.2020
摘要
α1-Adrenergic receptors (ARs) are catecholamine-activated G protein-coupled receptors (GPCRs) that are expressed in mouse and human myocardium and vasculature, and play essential roles in the regulation of cardiovascular physiology. Though α1-ARs are less abundant in the heart than β1-ARs, activation of cardiac α1-ARs results in important biologic processes such as hypertrophy, positive inotropy, ischemic preconditioning, and protection from cell death. Data from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) indicate that nonselectively blocking α1-ARs is associated with a twofold increase in adverse cardiac events, including heart failure and angina, suggesting that α1-AR activation might also be cardioprotective in humans. Mounting evidence implicates the α1A-AR subtype in these adaptive effects, including prevention and reversal of heart failure in animal models by α1A agonists. In this review, we summarize recent advances in our understanding of cardiac α1A-ARs.
科研通智能强力驱动
Strongly Powered by AbleSci AI